<DOC>
	<DOCNO>NCT02384577</DOCNO>
	<brief_summary>The main aim study investigate patient satisfaction treatment asthma COPD new device DuoResp® Spiromax® patient preference . Possible difficulty use device real-life condition clinical practice investigate .</brief_summary>
	<brief_title>Study Evaluate Satisfaction Usability DuoResp® SPIROMAX® Asthma COPD Treatment</brief_title>
	<detailed_description>The study detect instruction expense use inhaler , reason choice medication , switch treatment asthma COPD .</detailed_description>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>male female adult patient clinical diagnosis bronchial asthma chronic obstructive pulmonary disease patient regular medication inhale corticosteroid longacting beta2agonists fixeddose combination patient recently change medication DuoResp® Spiromax capacitate person present declaration consent disease contraindicate accordance summary product characteristic patient take part interventional clinical trial parallel last 4 week patient show condition disease might disturb monitor accord physician patient substance misuse case history ( drug , alcohol ) factor ( e.g . serious psychiatric condition ) limit ability participate study insufficient German language knowledge understand patient education complete questionnaire correct manner patient involve plan construction study ( Teva staff employee centre ) patient incapable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>